The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80% of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.

1.
Albertsson-Wikland K: Growth hormone in children with idiopathic short stature. Br Med J 2011;342:607-608.
2.
Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB: Effect of growth hormone (GH) treatment on the near-final height of 1,258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047-2054.
3.
Tanner JM: Catch-up growth in man. Br Med Bull 1981;37:233-238.
4.
Westphal O, Lindberg A: Final height in Swedish children with idiopathic growth hormone deficiency enrolled in KIGS treated optimally with growth hormone. Acta Paediatr 2008;97:1698-1706.
5.
Sas TC, de Ridder MA, Wit JM, Rotteveel J, Oostdijk W, Reeser HM, Otten BJ, De Muinck Keizer-Schrama SM: Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Horm Res Paediatr 2010;74:172-181.
6.
Albertsson-Wikland K, Rosberg S, Libre E, Lundberg LO, Groth T: Growth hormone secretory rates in children as estimated by deconvolution analysis of 24-hour plasma concentration profiles. Am J Physiol 1989;257:E809.
7.
Bang P, Ahmed SF, Argente J, Backeljauw P, Bettendorf M, Bona G, Coutant R, Rosenfeld RG, Walenkamp MJ, Savage MO: Identification and management of poor response to growth-promoting therapy in children with short stature. Clin Endocrinol (Oxf) 2012;77:169-181.
8.
Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO: Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res 2007;68:53-62.
9.
Kristrom B, Dahlgren J, Niklasson A, Nierop AF, Albertsson-Wikland K: The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 2009;9:1.
10.
Ranke MB, Lindberg A: Height at start, first-year growth response and cause of shortness at birth are major determinants of adult height outcomes of short children born small for gestational age and Silver-Russell syndrome treated with growth hormone: analysis of data from KIGS. Horm Res Paediatr 2010;74:259-266.
11.
Mericq V, Gajardo H, Eggers M, Avila A, Cassorla F: Effects of treatment with GH alone or in combination with LHRH analog on bone mineral density in pubertal GH-deficient patients. J Clin Endocrinol Metab 2002;87:84-89.
12.
Mul D, Wit JM, Oostdijk W, Van den BJ: The effect of pubertal delay by GnRH agonist in GH-deficient children on final height. J Clin Endocrinol Metab 2001;86:4655-4656.
13.
Mauras N, Gonzalez de PL, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K: Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008;93:823-831.
14.
Albertsson-Wikland K, Alm F, Aronsson S, Gustafsson J, Hagenas L, Hager A, Ivarsson S, Kristrom B, Marcus C, Moell C, Nilsson KO, Ritzen M, Tuvemo T, Westgren U, Westphal O, Aman J: Effect of growth hormone (GH) during puberty in GH-deficient children: preliminary results from an ongoing randomized trial with different dose regimens. Acta Paediatr Suppl 1999;88:80-84.
15.
Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J: High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc. Cooperative Study Group. J Clin Endocrinol Metab 2000;85:3653-3660.
16.
Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO: The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 2003;88:4748-4753.
17.
Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenas L, Ivarsson SA, Jonsson B, Kristrom B, Marcus C, Nilsson KO, Ritzen EM, Tuvemo T, Westphal O, Aman J: Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 2008;93:4342-4350.
18.
Carrascosa A, Audi L, Fernandez-Cancio M, Yeste D, Gussinye M, Albisu MA, Clemente M, Fabregas A, Bel J, Nosas R, Rabanal M, del Pozo C, Gomez JM, Mesa J: Growth hormone secretory status evaluated by growth hormone peak after two pharmacological growth hormone release stimuli did not significantly influence the two-year catch-up growth induced by growth hormone therapy in 318 prepubertal short children with idiopathic growth retardation. Horm Res Paediatr 2011;75:106-114.
19.
Carrascosa A, Audi L, Ferrandez-Cancio M, Yeste D, Gussinye M, Campos A, Albisu MA, Clemente M, Bel J, Nosas R, Rabanal M, del Pozo C, Gomez JM, Mesa J, and the Group for Short Stature: Height gain at adult-height age in 184 short patients treated with growth hormone (GH) from prepubertal age to near adult-height age is not related to GH secretory status at GH therapy onset. Horm Res Paediatr 2013 (E-pub ahead of print).
20.
Rikken B, Massa GG, Wit JM: Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Dutch Growth Hormone Working Group. Horm Res 1995;43:135-137.
21.
Carel JC, Ecosse E, Nicolino M, Tauber M, Leger J, Cabrol S, Bastie-Sigeac I, Chaussain JL, Coste J: Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow-up study of the French population-based registry. Br Med J 2002;325:70.
22.
Fujieda K, Tanaka T, Takano K, Chihara K, Seino Y, Irie M: Adult height after growth hormone treatment in Japanese children with idiopathic growth hormone deficiency: analysis from the KIGS Japan database. J Pediatr Endocrinol Metab 2011;24:457-462.
23.
Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG: Height velocity targets from the National Cooperative Growth Study for first-year growth hormone responses in short children. J Clin Endocrinol Metab 2008;93:352-357.
24.
Ranke MB, Lindberg A: Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010;95:1229-1237.
25.
Kriström B, Albertsson Wikland K: Growth prediction models, concept and use. Horm Res 2002;57(suppl 2):66-70.
26.
Ranke MB, Lindberg A: Prediction models for short children born small for gestational age covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database). BMC Med Inform Decis Mak 2011;11:38.
27.
Albertsson-Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop AF: Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Pediatr Res 2000;48:475-484.
28.
Schonau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, Bramswig J, Blum WF: A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol 2001;144:13-20.
29.
Van Buuren S: Flexible Imputation of Missing Data. Interdisciplinary Statistic Series. Boca Raton, Chapman & Hall/CRC, 2012.
30.
Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999;84:1174-1183.
31.
Ranke MB, Lindberg A: Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009;19:1-11.
32.
Ranke MB, Lindberg A: Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review. Horm Res Paediatr 2011;75:423-432.
33.
Kristrom B, Lofqvist C, Rosberg S, Albertsson-Wikland K: Effect of spontaneous GH secretion and the GH sampling period on the accuracy of models for predicting growth responses to GH treatment. J Clin Endocrinol Metab 2001;86:4963-4964.
34.
Dahlgren J, Kristrom B, Niklasson A, Nierop AF, Rosberg S, Albertsson-Wikland K: Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak 2007;7:40.
35.
Gelander L, Albertsson-Wikland K: Growth hormone (GH) release after administration of GH-releasing hormone in relation to endogenous 24-h GH secretion in short children. J Endocrinol 1989;122:61-68.
36.
Kristrom B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K: Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 2009;94:483-490.
37.
Kristrom B, Karlberg J, Albertsson-Wikland K: Prediction of the growth response of short prepubertal children treated with growth hormone. Swedish Paediatric Study Group for GH treatment. Acta Paediatr 1995;84:51-57.
38.
Land C, Blum WF, Shavrikova E, Kloeckner K, Stabrey A, Schoenau E: Predicting the growth response to growth hormone (GH) treatment in prepubertal and pubertal children with isolated GH deficiency - model validation in an observational setting (GeNeSIS). J Pediatr Endocrinol Metab 2007;20:685-693.
39.
De Ridder MA, Stijnen T, Hokken-Koelega AC: Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab 2007;92:925-931.
40.
De Ridder MA, Stijnen T, Hokken-Koelega AC: Prediction model for adult height of small for gestational age children at the start of growth hormone treatment. J Clin Endocrinol Metab 2008;93:477-483.
41.
Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, Kristrom B, Tapanainen P, Aberg V: A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr 2011;75:335-345.
42.
Ranke MB, Lindberg A, Chatelain P, Wilton P, Price DA, Albertsson-Wikland K: The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Horm Res 2001;55(suppl 2):44-48.
43.
Decker R, Albertsson-Wikland K, Kristrom B, Nierop AF, Gustafsson J, Bosaeus I, Fors H, Hochberg Z, Dahlgren J: Metabolic outcome of GH treatment in prepubertal short children with and without classical GH deficiency. Clin Endocrinol (Oxf) 2010;73:346-354.
44.
Jung H, Land C, Nicolay C, De Schepper J, Blum WF, Schonau E: Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. Eur J Endocrinol 2009;160:149-156.
45.
Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG: Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002;87:90-98.
46.
Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480-2486.
47.
Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG: Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010;95:2089-2098.
48.
Cohen P, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, Germak J, American Norditropin Study Group: Efficacy of IGF-based growth hormone (GH) dosing in non-GH-deficient (non-GHD) short stature children with low IGF-I is not related to basal IGF-I levels. Clin Endocrinol (Oxf) 2013;78:405-414.
49.
Cianfarani S, Tondinelli T, Spadoni GL, Scire G, Boemi S, Boscherini B: Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clin Endocrinol (Oxf) 2002;57:161-167.
50.
Cianfarani S, Liguori A, Boemi S, Maghnie M, Iughetti L, Wasniewska M, Street ME, Zucchini S, Aimaretti G, Germani D: Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. J Clin Endocrinol Metab 2005;90:6028-6034.
51.
Lofqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson-Wikland K: Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 2001;86:5870-5876.
52.
Kristrom B, Jansson C, Rosberg S, Albertsson-Wikland K: Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment. J Clin Endocrinol Metab 1997;82:2889-2898.
53.
Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G: IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Horm Res 2005;64:68-76.
54.
Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG: The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 2001;86:5176-5183.
55.
Coutant R, Dorr HG, Gleeson H, Argente J: Diagnosis of endocrine disease: limitations of the IGF1 generation test in children with short stature. Eur J Endocrinol 2012;166:351-357.
56.
Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppala M: Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-2615.
57.
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M: Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-1280.
58.
Van der Kaay DC, Hendriks AE, Ester WA, Leunissen RW, Willemsen RH, de Kort SW, Paquette JR, Hokken-Koelega AC, Deal CL: Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age. Growth Horm IGF Res 2009;19:198-205.
59.
Chen HY, Chan IH, Sham AL, Leung VH, Ma SL, Ho SC, Tang NL: Haplotype effect in the IGF1 promoter accounts for the association between microsatellite and serum IGF1 concentration. Clin Endocrinol (Oxf) 2011;74:520-527.
60.
Dos SC, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P: A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004;36:720-724.
61.
Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA: Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab 2009;94:3721-3730.
62.
Renehan AG, Solomon M, Zwahlen M, Morjaria R, Whatmore A, Audi L, Binder G, Blum W, Bougneres P, Santos CD, Carrascosa A, Hokken-Koelega A, Jorge A, Mullis PE, Tauber M, Patel L, Clayton PE: Growth hormone receptor polymorphism and growth hormone therapy response in children: a bayesian meta-analysis. Am J Epidemiol 2012;175:867-877.
63.
Costalonga EF, Antonini SR, Guerra-Junior G, Coletta RR, Franca MM, Braz AF, Mendonca BB, Arnhold IJ, Jorge AA: Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency. Pharmacogenomics J 2012;12:439-445.
64.
Braz AF, Costalonga EF, Montenegro LR, Trarbach EB, Antonini SR, Malaquias AC, Ramos ES, Mendonca BB, Arnhold IJ, Jorge AA: The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome. J Clin Endocrinol Metab 2012;97:E671-E677.
65.
Stevens A, Clayton P, Tato L, Yoo HW, Rodriguez-Arnao MD, Skorodok J, Ambler GR, Zignani M, Zieschang J, DellaCorte G, Destanaves B, Champigneulle A, Raelson J, Chaterlain P, and the PREDICT Investigator Group: Pharmacogenomics of insulin-like growth factor-I generation during growth hormone (GH) treatment in children with GH deficiency or Turner syndrome. Pharmacogenomics J 2013 (E-pub ahead of print).
66.
Hellgren G, Andersson B, Nierop AF, Dahlgren J, Hochberg Z, Albertsson-Wikland K: A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature. Proteome Sci 2008;6:35.
67.
Andersson B, Hellgren G, Nierop AF, Hochberg Z, Albertsson-Wikland K: Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone treatment in short prepubertal children. Proteome Sci 2009;7:40.
68.
Geffner ME, Dunger DB: Future directions: growth prediction models. Horm Res 2007;68(suppl 5):51-56.
69.
Ranke MB, Lindberg A, Brosz M, Kaspers S, Loftus J, Wollmann H, Koltowska-Haggstrom M, Roelants M: Accurate long-term prediction of height during the first four years of growth hormone treatment in prepubertal children with growth hormone deficiency or Turner syndrome. Horm Res Paediatr 2012;78:8-17.
70.
Savage MO, Burren CP, Rosenfeld RG: The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf) 2010;72:721-728.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.